Journal
JOURNAL OF EXPERIMENTAL MEDICINE
Volume 209, Issue 11, Pages 2033-2047Publisher
ROCKEFELLER UNIV PRESS
DOI: 10.1084/jem.20120493
Keywords
-
Categories
Funding
- Austrian Science Fund (FWF) [P22058, P19245, SFB-2304]
- National Institutes of Health [R01 AI077058, CA014195]
- Austrian Science Fund (FWF) [P 22058] Funding Source: researchfish
- Austrian Science Fund (FWF) [P22058, W1212] Funding Source: Austrian Science Fund (FWF)
Ask authors/readers for more resources
Transforming growth factor-beta 1 (TGF-beta 1) is a fundamental regulator of immune cell development and function. In this study, we investigated the effects of TGF-beta 1 on the differentiation of human Langerhans cells (LCs) and identified Axl as a key TGF-beta 1 effector. Axl belongs to the TAM (Tyro3, Axl, and Mer) receptor tyrosine kinase family, whose members function as inhibitors of innate inflammatory responses in dendritic cells and are essential to the prevention of lupus-like autoimmunity. We found that Axl expression is induced by TGF-beta 1 during LC differentiation and that LC precursors acquire Axl early during differentiation. We also describe prominent steady-state expression as well as inflammation-induced activation of Axl in human epidermal keratinocytes and LCs. TGF-beta 1-induced Axl enhances apoptotic cell (AC) uptake and blocks proinflammatory cytokine production. The antiinflammatory role of Axl in the skin is reflected in a marked impairment of the LC network preceding spontaneous skin inflammation in mutant mice that lack all three TAM receptors. Our findings highlight the importance of constitutive Axl expression to tolerogenic barrier immunity in the epidermis and define a mechanism by which TGF-beta 1 enables silent homeostatic clearing of ACs to maintain long-term self-tolerance.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available